Micogel

Quick links to important sections

Micogel

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micogel

Property Description
Active Ingredient Miconazole Nitrate
Form Topical Gel or Cream
Pharmacological Class Antifungal Agent (Azole/Imidazole)
Common Use Combating superficial fungal and yeast infections
Origin Synthetic

Definition and Pharmacological Class

Micogel is a recognized topical pharmaceutical preparation whose identity is rooted in its active compound, Miconazole, commonly prepared as Miconazole Nitrate. It is fundamentally classified as an antifungal agent, designed to address fungal and yeast overgrowth on the skin or mucous membranes. This classification places Miconazole within the Imidazole sub-group of the broader Azole family of medications. As an imidazole antifungal, the medicine is categorized to fight fungal infections.

Miconazole is a synthetic derivative that belongs to a class of compounds known for targeting specific fungal cell structures. The drug’s general purpose is clinically recognized for providing the necessary action to manage superficial fungal infections, thereby relieving associated discomfort. Topical Miconazole has a long history of use in treating common fungal infections due to its spectrum of activity, and the drug is a well-established treatment option for these types of conditions.


Composition, Origin, and Form

The core of the drug is the single active ingredient, Miconazole Nitrate, which is formulated into a semi-solid, hydrophilic gel base for topical use. This specific gel formulation is a key differentiating factor, often positioned for application on mucosal surfaces or areas requiring a non-greasy, water-miscible vehicle, unlike traditional hydrophobic antifungal creams.

As a single active ingredient product, the entire therapeutic benefit is derived exclusively from the Miconazole compound. The topical formulation ensures the medication is delivered directly to the site of the infection, maximizing the local concentration of the antifungal agent.

What side effects are possible with Micogel?

Possible Side Effects and Safety Information

The official safety profile for Micogel, which contains Miconazole Nitrate, primarily details local reactions and, rarely, systemic immune responses. The most frequently documented adverse reactions involve the skin and the application site.


Adverse Reaction Scope

Category Regulatory Classification
Uncommon Reactions Skin burning sensation, Skin inflammation, Skin hypopigmentation.
Application Site Reactions Irritation, burning, pruritus (itching), warmth.
Serious Adverse Reactions Anaphylactic reaction, Angioedema (swelling of the face, tongue, or throat), Severe allergic reactions.

Safety Considerations

The adverse reactions are categorized under System-Organ Classes including Skin and Subcutaneous Tissue Disorders and Immune System Disorders. The most severe events, such as Anaphylactic reaction, are classified as Very Rare in regulatory documentation.

Micogel is formally contraindicated in individuals with a known hypersensitivity to Miconazole Nitrate or other related imidazole derivatives. Official safety data also notes that due to potential absorption, the use of topical Miconazole may increase the effects and side effects of some concurrent oral anticoagulants, such as warfarin.

Regarding specific populations, regulatory documents state that no different side effects are expected in pediatric or older adult populations compared to adults. Additionally, excessive use has been noted to potentially cause skin irritation, which typically resolves upon discontinuation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Micogel (Miconazole Nitrate) topical preparations defines overdose primarily by the route of exposure rather than typical usage. Following normal cutaneous application, the absorption of Miconazole into the systemic circulation is minimal (less than 1%), rendering a severe systemic overdose unlikely. The primary documented clinical concerns relate to the accidental ingestion of large quantities of the gel or cream formulation.

Documented Overdose Manifestations

Exposure Context Official Regulatory Findings
Accidental Oral Ingestion Gastrointestinal disturbances, including vomiting and diarrhea are the documented symptoms.
Excessive Topical Use Localized effects such as skin irritation may occur, which typically resolve upon product discontinuation.

Required Emergency Actions

If accidental ingestion of large quantities of the product occurs, regulatory information mandates that the patient seek immediate medical attention and contact a Poison Control Center for advice. Management of a confirmed overdose is confined to symptomatic and supportive treatment, including close monitoring in a clinical setting. No specific antidote is known for Miconazole overdose, and certain regulatory labels indicate that procedures like gastric lavage may be considered following recent, large ingestion. Urgent medical review is required when large ingestion is suspected.

Therapeutic Uses of Micogel

What Micogel Treats: Main Uses and Benefits

Micogel, which contains the antifungal agent miconazole, is applied in addressing fungal infections in clinical settings where short-term symptomatic assistance is needed. The medication is commonly used to help with conditions presenting with systemic or localized discomfort caused by dermatophytes and yeast. Miconazole is considered relevant for easing the overall symptom burden in conditions like tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), and cutaneous candidiasis (skin yeast infections).

These are conditions involving episodic or fluctuating manifestations, often marked by symptoms related to inflammatory or irritative states of the skin. Topical miconazole helps address symptom clusters that may become intense or disruptive, such as itching, burning, and scaling of the skin. By supporting the patient during difficult episodes, it may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Supports the management of symptoms related to Itching and Scaling

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope and Restrictions

Micogel (Topical Miconazole) is contraindicated in individuals with a known hypersensitivity to miconazole nitrate, other imidazole derivatives, or to any excipients present in the formulation. This represents the primary, absolute regulatory exclusion.

For age-related eligibility, the medicine is not recommended in infants less than four weeks of age because efficacy was not demonstrated in this specific group. For the geriatric population (aged 65 and over), official prescribing information indicates that safety and effectiveness have not been evaluated in dedicated clinical studies.

Use is also subject to regulatory limitations in certain special populations: safety and effectiveness have not been established in very-low-birth-weight infants or in immunocompromised patients.

Regarding physiological states, Micogel is classified for conditional use during pregnancy and lactation. This classification is due to the lack of adequate, well-controlled studies in pregnant women, and because it is not known if the active components are excreted in human milk. Specific restrictions related to severe hepatic or renal impairment are not explicitly documented for topical use, given the minimal systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Micogel, containing the active ingredient Miconazole, is defined by the potential for pharmacokinetic interference with certain systemically absorbed oral medications. While systemic absorption from the topical formulation is limited, official regulatory information documents the potential for clinically significant interactions.


Metabolic Interaction Basis

Miconazole is a documented inhibitor of the cytochrome P450 enzymes CYP2C9 and CYP3A4. This official classification establishes an interaction pattern where the clearance of co-administered drugs that are substrates of these enzymes may be reduced, potentially leading to increased plasma concentrations.


Documented Interacting Substances

Interactions are officially documented with the following categories, based on the potential for enhanced drug exposure:

Substance Category Documented Interaction Outcome
Oral Anticoagulants (e.g., Warfarin) Enhanced anticoagulant effect, resulting in an increased International Normalized Ratio (INR) and bleeding risk.
Oral Hypoglycemics (e.g., Sulfonylureas) Increased effects and side effects of the hypoglycemic agent.
Anticonvulsants (e.g., Phenytoin) Increased effects and side effects of Phenytoin.

Interaction-Related Restrictions

The base material of certain vaginal suppository formulations may interact with and damage latex products such as condoms or diaphragms, which can result in a loss of their barrier function. The regulatory information for the topical cream or gel does not include mandatory timing-based separation rules for co-administration.

Mechanism of Action

The mechanism of Miconazole Nitrate involves the targeted interference with fundamental processes required for fungal cell survival, resulting in structural disruption.

Targeting the Ergosterol Biosynthesis Pathway

The drug's primary action is the inhibition of Cytochrome P450 14alpha-demethylase (CYP51), an essential enzyme within the fungal cell. By blocking this enzyme, Miconazole prevents the conversion of lanosterol into ergosterol, the key sterol necessary for fungal membrane integrity. This molecular blockade immediately arrests the pathogen's ability to create viable cellular structures and leads to the cessation of fungal cell replication.


Fungal Membrane Disruption and Cellular Failure

The enzymatic inhibition triggers a cascade where essential ergosterol is depleted while toxic 14alpha-methyl sterols accumulate and integrate into the cell barrier. This toxic accumulation compromises the fungal cell's stability, increasing its permeability and causing the loss of internal contents. This structural failure ultimately results in the fungicidal effect—the destruction of the pathogenic fungal population—which is the biological event that leads to the biological clearance of the pathogenic fungal population.

Dosage and Administration Information

Micogel, a 2% topical preparation containing Miconazole Nitrate, is administered exclusively via the cutaneous route for external application only. The instructions for use establish a standardized protocol defined by specific application technique, frequency, and duration.

Before applying the medication, the affected area of the skin must be cleansed and dried thoroughly. A thin layer of the 2% formulation is then applied to the entire affected area and the surrounding skin border. The standard dosing regimen specifies application twice daily (morning and evening), and this fixed frequency pattern is maintained throughout the required duration of the therapeutic course.

The mandated duration varies by the site of infection: treatment for Tinea Corporis (ringworm) and Tinea Pedis (athlete’s foot) typically requires 4 weeks of consistent use, while Tinea Cruris (jock itch) and Cutaneous Candidiasis require a course of 2 weeks. The treatment protocol also specifies that use must continue for the full prescribed time, even if physical signs of the infection disappear earlier.

This product is not authorized for infections of the scalp or nails and is approved for use in children 2 years of age and older. If a scheduled application is missed, it is applied as soon as it is remembered, unless it is nearly time for the next scheduled dose, in which case the regular schedule is followed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Micogel

Evidence for use in Superficial Fungal Infections (Dermatophytoses)

The research exploring Micogel for common superficial fungal infections like athlete's foot and ringworm is based on short-term Randomized Controlled Trials (RCTs). Researchers monitored outcomes like Mycological Cure (laboratory confirmation of fungal clearance) and Clinical Cure (assessment of symptom change, such as itching and scaling). Many trials reported measurements consistent with the study objectives when Miconazole was evaluated against a non-medicated vehicle base. However, research exploring head-to-head performance against all newer antifungal classes is sometimes limited or has yielded mixed findings.

Evidence for use in Skin and Mucosal Yeast Infections (Candidiasis)

The evidence for use in yeast infections, or cutaneous candidiasis, also comes from RCTs. Studies monitored responses over defined time intervals, reporting measurements consistent with the study objectives for symptom change and clearance endpoints when the infection was caused by Candida albicans. Some trials reported that infections caused by non-albicans species, such as Candida glabrata, described lower measured clearance rates. Research has explored the use of the medicine in children, including infants and neonates, specifically for candidal diaper dermatitis.

Long-Term Outcomes and Follow-Up in Research

The research exploring short-term symptom changes typically involves defined follow-up periods that extend for only a few weeks beyond the cessation of treatment. This means that long-term effects are not fully established based on the primary clinical trial data. Studies monitored patterns related to recurrence for all indications, but the available data provides limited insight into how frequently or why infections might return, or into the sustained durability of the effect years after use.

What is Still Uncertain in the Research Record

The available research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain. Data for certain fungal species remain insufficient, and the long-term outcomes related to recurrence and sustained clearance are not well characterized. The evidence quality varies across studies, and many older trials are limited by smaller sample sizes and methodological inconsistencies.

Key Studies & References

  1. Efficacy of topical antifungal drugs in different dermatomycoses: a systematic review with meta-analysis
  2. Consensus for the Treatment of Tinea Pedis: A Systematic Review of Randomised Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Micogel (FAQ)


Q: What is Micogel used for, besides the main condition mentioned?

Official regulatory documents confirm that Micogel (Miconazole Nitrate topical) is indicated for treating Tinea pedis (athlete’s foot), Tinea cruris (jock itch), Tinea corporis (ringworm), and Cutaneous Candidiasis (skin yeast infections). Some regulatory documents also note that it may be used to treat Pityriasis versicolor or where infections involve certain gram-positive bacteria.

Q: Are there different strengths or forms of Micogel available?

Micogel is most commonly approved as a 2% topical preparation and is available as a cream or gel. The active ingredient, Miconazole, is also formulated into topical powders, lotions, or spray forms under various regulatory approvals in different regions.

Q: How quickly should I expect to see an effect from Micogel?

Official guidance notes that if there is no improvement in the treated condition, a healthcare professional may be consulted. The label indicates this consultation may be appropriate if there is no improvement within 2 weeks for infections like jock itch, or 4 weeks for conditions like athlete's foot or ringworm.

Q: How long does Micogel typically stay in my system after the last use?

Official product information indicates that when Micogel is applied to the skin, less than 1% of the active ingredient is absorbed into the bloodstream. This minimal absorption suggests the medicine is typically eliminated from the body relatively quickly after application is stopped.

Q: What are common reasons people stop using Micogel?

Regulatory documents state that the course of treatment is intended to be completed for the full prescribed duration. Discontinuation is officially indicated if a user experiences signs of a severe allergic reaction or if the application site irritation worsens significantly, or if the infection does not improve or appears to worsen during the treatment period.

Q: Does Micogel interact with common pain relievers like ibuprofen?

The potential for drug-drug interactions is primarily based on Miconazole's ability to affect certain liver enzymes, which is relevant to oral (systemically absorbed) medications. Regulatory documents for the topical product do not typically list common, non-enzyme-dependent pain relievers like ibuprofen as documented interacting substances.

Q: Can I use Micogel if I am currently taking birth control pills?

Miconazole is a documented inhibitor of certain liver enzymes. While systemic absorption from the topical form is minimal, the oral contraceptive category is noted in regulatory documents for systemically absorbed miconazole products as a potential interaction risk. Individuals using oral contraceptives may review the information with a healthcare professional.

Q: Does using Micogel affect my ability to drive or operate machinery?

Official regulatory documents typically state that because the topical product has minimal systemic absorption (gets very little into the bloodstream), the medicine is expected to have no or negligible influence on the ability to drive or operate machinery.

Q: Are there any specific foods or drinks that should be avoided when using Micogel?

Official regulatory documents for the topical formulation of Micogel generally do not contain mandatory warnings or instructions about avoiding specific foods or drinks while the medicine is being used.

Q: Is there a generic version of Micogel available?

The active ingredient in Micogel is Miconazole Nitrate. Once a drug's patent protections have expired, the regulatory framework in many regions allows for generic manufacturers to produce and market their own products containing Miconazole Nitrate.

Q: Are there known interactions between Micogel and herbal supplements like St. John's Wort?

Although herbal supplements are not always explicitly listed, the potential for interaction with certain substances exists due to the effect on liver enzymes. St. John’s Wort is sometimes officially noted as a potential interaction risk for systemically absorbed drugs that utilize the same enzyme pathway that Miconazole can affect.

Q: What should I do if the Micogel packaging appears damaged?

Official guidelines emphasize that all medicines must be kept in their original container until use. Official guidelines indicate that product use should be limited to those where the packaging and medicine appear intact and uncontaminated.

Q: Is there any information about using Micogel for chronic conditions?

Micogel is officially authorized for the short-term treatment of specified acute fungal infections, with typical durations of 2 or 4 weeks. The regulatory indications do not include the long-term management of chronic conditions.

Q: What is the shelf life of Micogel once the package is opened?

While the manufacturer sets a definitive expiration date, general official guidance for topical products in tubes often recommends discarding the product after a maximum of three to six months after opening, unless a different 'in-use' shelf life is specified on the packaging.

Q: Can men and women use Micogel for the same indications?

Yes, regulatory documents indicate that Micogel is authorized for the treatment of conditions like ringworm, athlete’s foot, jock itch, and cutaneous candidiasis. These are conditions that affect both men and women, and the indications are not gender-specific.

Q: Are there any reported cases of resistance developing to Micogel?

Miconazole is an established antifungal agent. Regulatory and scientific reviews have addressed the potential for resistance development, noting that infections caused by certain non-albicans Candida species have sometimes shown lower measured clearance rates in clinical studies.

Q: Does alcohol consumption impact the effectiveness or safety of Micogel?

Official regulatory documents for the topical preparation of Micogel generally do not contain warnings or specific instructions regarding the consumption of alcohol during its use.

Q: Is Micogel safe for individuals with pre-existing heart conditions?

The topical product is not typically associated with systemic effects on the heart due to minimal systemic absorption. However, regulatory documents caution that high systemic levels of miconazole (such as with oral forms) can interact with drugs that affect the heart's rhythm (QT interval).

Q: Can Micogel interact with common anti-depressant medications?

The potential for interaction exists with anti-depressants that are metabolized by the liver enzymes CYP2C9 or CYP3A4, which Miconazole can inhibit. This is the metabolic basis for concern with systemically absorbed drugs, though specific anti-depressants are not always explicitly listed for the topical product.

Q: What should I do if I accidentally get Micogel in my eyes?

Official warnings state that the medicine should strictly avoid contact with the eyes. If accidental exposure occurs, regulatory warnings advise that the affected eye be washed out immediately and thoroughly with running water.

Q: What happens if Micogel is used for something it is not indicated for?

Micogel is authorized only for specified fungal and yeast infections of the skin. The regulatory label specifically states that the product is not effective on the scalp or nails, and using it for unauthorized purposes may result in a lack of treatment effectiveness and potentially cause skin irritation.

Q: Is Micogel considered a prescription-only medicine in most regions?

In many regions, Miconazole Nitrate 2% topical cream/gel is classified as an Over-the-Counter (OTC) medicine. This classification means it can be purchased and used without needing a prescription from a doctor.

Q: Are there any specific laboratory tests required before or during the use of Micogel?

Routine laboratory tests are not required for the general patient population using the topical medicine. Monitoring of blood tests may only be necessary if the medicine is used at the same time as certain oral anticoagulant medications, like Warfarin.

Q: Does Micogel have any known effect on fertility?

While regulatory data often includes non-clinical studies in animals showing no direct effect on fertility, official guidance sometimes notes that human studies are not sufficient to definitively rule out any potential effects.

Q: What is the difference between Micogel and similar over-the-counter treatments?

Micogel contains Miconazole, which is classified as an Imidazole-class antifungal. Other common OTC treatments may contain different active ingredients, such as Allylamines (like Terbinafine) or other types of Azoles (like Clotrimazole), which belong to distinct chemical drug classes.

Q: What is the difference between the active ingredient in Micogel and other treatments?

The active ingredient, Miconazole, is chemically defined as an Imidazole derivative. This compound is known for its dual action against both dermatophytes (like ringworm) and yeasts, which distinguishes it in terms of its overall spectrum of activity within the antifungal drug class.

Q: What is the recommended approach if a mild side effect is experienced?

Common mild side effects, such as a burning sensation, itching, or irritation, are typically transient and usually resolve on their own. Regulatory guidance indicates that consulting a healthcare professional may be appropriate if the irritation worsens significantly or if a severe allergic reaction occurs.

Q: Does Micogel affect blood sugar levels, which is a concern for people with diabetes?

Micogel does not have a stated direct effect on blood sugar levels. However, official documents confirm that Miconazole can potentially increase the effects of certain oral hypoglycemic agents (medications used to treat high blood sugar) due to its metabolic interaction with liver enzymes.

Q: Is Micogel safe to use for a long period, or is it only for short-term use?

Micogel is authorized for short-term use only, with a defined treatment duration of up to 4 weeks. Regulatory documents indicate that consultation with a healthcare professional is appropriate if the skin condition persists or worsens after completing the full recommended treatment duration.

Q: What should I do if the Micogel packaging appears damaged?

Official guidelines emphasize that medicines should be stored in their original container and should only be used if the product and container appear intact and uncontaminated. If the packaging is compromised, guidance on safe disposal may be obtained from the dispensing source.

How should Micogel be stored and disposed of?

How to Store and Dispose of Micogel

Micogel (miconazole nitrate topical) must be stored and handled according to regulatory labeling to ensure product integrity and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20^circC to 25^circC (68°F to 77°F).
Protection Protect from freezing, excessive heat, moisture, and direct light.
Container Keep in the original container and ensure the cap is tightly closed.
Safety Store out of the sight and reach of children.

Disposal Instructions

Unused or expired Micogel should be discarded safely by following official guidelines. The product must not be flushed down the toilet or poured down the sink. If a drug take-back program is unavailable, mix the medicine with an undesirable substance, seal it in a bag, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Micogel found in:

A-Z Index: